|Day's Range||128.26 - 129.01|
|52 Week Range||101.87 - 129.77|
|PE Ratio (TTM)||63.49|
|Expense Ratio (net)||0.06%|
In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.
In 2016, Celgene’s (CELG) Otezla generated revenues of around $1.0 billion, a 116% year-over-year (or YoY) increase.
After Dupixent's commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.